A FtsZ inhibitor-acinetobactin conjugate with enhanced cellular uptake in Acinetobacter baumannii acts synergistically in combination with PBP3-targeting antibiotics
PLOS One · 2025
DOI: 10.1371/journal.pone.0334409 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Eric J Bryan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, United States of America. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Cytoskeletal Proteins, Bacterial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Jersey Health Foundation, Rutgers, The State University of New Jersey, Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
Multidrug resistance in the Gram-negative bacterial pathogen Acinetobacter baumannii is a global public health threat, highlighting a critical need for drug development. FtsZ is an essential cell division protein that is an appealing target for new antibacterial agents. Benzamide-based FtsZ inhibitors have been developed that exhibit potent activity against Gram-positive pathogens, but poor activity against A. baumannii and other clinically significant Gram-negative pathogens. In this connection, we have initiated a program to enhance activity of benzamide FtsZ inhibitors via conjugation to iron-coordinating siderophore moieties that promote cellular uptake through endogenous bacterial siderophore-iron uptake pathways. Here, we describe a second-generation FtsZ inhibitor-siderophore conjugate (RUP7), in which an oxazole-benzamide FtsZ inhibitor is conjugated to acinetobactin, a principal native siderophore of A. baumannii . In iron-limiting conditions that are typically present at common sites of A. baumannii infection, RUP7 exhibits significantly enhanced activity against a library of A. baumannii clinical isolates relative to the non-conjugated FtsZ inhibitor (RUP2) or a first-generation conjugate (RUP4) in which RUP2 has been conjugated to a chlorocatechol siderophore functionality. This enhanced activity is correlated with markedly improved cellular uptake, perhaps via the BauABCDEF acinetobactin-iron uptake system, the expression of which is highly upregulated in iron-limiting conditions. RUP7 exhibits significant bactericidal synergy against A. baumannii when combined with clinical antibiotics that target penicillin binding protein 3 (PBP3 or FtsI), including aztreonam, piperacillin:tazobactam, cefsulodin, and ceftazidime. In the aggregate, our results highlight the combination of design-optimized FtsZ inhibitor-siderophore conjugates and PBP3-targeting antibiotics as an appealing therapeutic strategy for the treatment of A. baumannii infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, United States of America.
- Department of Molecular Design and Synthesis, Office for Research, Rutgers University Core Services, Piscataway, New Jersey, United States of America.
- Rosalind Franklin Institute, Harwell Science and Innovation Campus, Oxford, United Kingdom.
ORCID-Profile: Lucile Moynié, Daniel S Pilch
Förderung
- New Jersey Health Foundation
- Rutgers, The State University of New Jersey
- Engineering and Physical Sciences Research Council
Zitieren
APA
Bryan, E. J., Szekely, Z., Wang, Y., Fan, H., Moynié, L., Roberge, J. Y., & Pilch, D. S. (2025). A FtsZ inhibitor-acinetobactin conjugate with enhanced cellular uptake in Acinetobacter baumannii acts synergistically in combination with PBP3-targeting antibiotics. PLOS One. https://doi.org/10.1371/journal.pone.0334409
Vancouver
Bryan EJ, Szekely Z, Wang Y, Fan H, Moynié L, Roberge JY, et al. A FtsZ inhibitor-acinetobactin conjugate with enhanced cellular uptake in Acinetobacter baumannii acts synergistically in combination with PBP3-targeting antibiotics. PLOS One. 2025. doi:10.1371/journal.pone.0334409
BibTeX
@article{Bryan2025,
author = {Bryan, Eric J and Szekely, Zoltan and Wang, Yuxuan and Fan, Huizhou and Moynié, Lucile and Roberge, Jacques Y and Pilch, Daniel S},
title = {A FtsZ inhibitor-acinetobactin conjugate with enhanced cellular uptake in Acinetobacter baumannii acts synergistically in combination with PBP3-targeting antibiotics},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334409}
}
EUVIMED